¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"population study"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • population policy
    Àα¸Á¤Ã¥
  • population pyramid
    Àα¸¸ðÇü, Àα¸ÇǶó¹Ìµå
  • population trend
    Àα¸Ãß¼¼
  • population variance
    ¸ðÁý´ÜºÐ»ê
  • reference population
    ±âÁØÁý´Ü
  • stable population
    ¾ÈÁ¤Àα¸
  • standard population
    Ç¥ÁØÀα¸
  • stationary population
    °íÁ¤Àα¸
  • target population
    Ç¥ÀûÁý´Ü
  • virgin population
    ¹«³ëÃâÀα¸
  • air study
    °ø±âÁÖÀÔ°Ë»ç
  • cohort study
    ÄÚȣƮ¿¬±¸, ÄÚȣƮÁ¶»ç
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
  • crossover study
    ±³Â÷¿¬±¸
  • cross-sectional study
    ´Ü¸é¿¬±¸
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • pilot study
    ¿¹ºñ¿¬±¸
  • prospective study
    ÀüÇ⿬±¸, °èȹ¿¬±¸, ¾Õ¹æÇ⿬±¸, Àü¸Á¿¬±¸
  • prospective cohort study
    ÀüÇâÄÚȣƮ¿¬±¸
  • retrospective study
    ÈÄÇ⿬±¸, µÞ¹æÇ⿬±¸, ȸ°í¿¬±¸
  • retrospective cohort study
    ÈÄÇâÄÚȣƮ¿¬±¸
  • single blinding study
    ´Ü¼ø¸Í°Ë¹ý
  • urodynamic study
    ¿ä¿ªµ¿Çа˻ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • population pyramid
    Àα¸¸ðÇü, Àα¸ÇǶó¹Ìµå
  • population trend
    Àα¸Ãß¼¼
  • population variance
    ¸ðÁý´ÜºÐ»ê
  • population attributable risk
    ÀϹÝÀα¸±â¿©À§Çèµµ
  • population excess rate
    ¸ðÁý´ÜÃʰúÀ²
  • population mortality table
    ±¹¹Î»ç¸Á·üÇ¥
  • reference population
    ±âÁØÁý´Ü
  • stable population
    ¾ÈÁ¤Àα¸
  • standard population
    Ç¥ÁØÀα¸
  • stationary population
    Á¤ÁöÀα¸
  • target population
    Ç¥ÀûÁý´Ü
  • virgin population
    ¹«³ëÃâÀα¸
  • air study
    °ø±âÁÖÀÔ°Ë»ç
  • arterial blood gas study
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • cardiac gated MR study
    ½ÉÀ嵿±âÀÚ±â°ø¸í°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • population genetics
    Áý´ÜÀ¯ÀüÇÐ(ÊÙËôËøÌ°).
  • population growth
    Àα¸¼ºÀå(ËöË´ËÛËö).
  • population increase
    Àα¸Áõ°¡(ÊÙ̡˧).
  • population mean
    ¸ðÆò±Õ(ËḬ̂˻).
  • population mortality table
    ±¹¹Î»ý¸íÇ¥(Ë´ËÑË×ËḬ̂), ±¹¹Î»ç¸Á·üÇ¥(Ë´ËÑË×ËÎ Ëô̰).
  • population mutation
    Áý´Ü±ºµ¹¿¬º¯ÀÌ(¡­ÔÍæÔܨì¶).
  • population policy
    Àα¸Á¤Ã¥(ÊÙËøÌ¤).
  • population problem
    Àα¸¹®Á¦.
  • population pyramid
    Àα¸¸ðÇü(ËöË´ËÎÌ´).
  • population screening
    Áý´Ü°ËÁø(̤ËÀ˧̤).
  • population trend
    Àα¸Ãß¼¼(ÊÙ̧ËÛ).
  • population variance
    ¸ðºÐ»ê(ËÎËÓË×).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • population increase
    Àα¸Áõ°¡(ÊÙ̡˧).
  • population mean
    ¸ðÆò±Õ(ËḬ̂˻).
  • population mortality table
    ±¹¹Î»ý¸íÇ¥(Ë´ËÑË×ËḬ̂), ±¹¹Î»ç¸Á·üÇ¥(Ë´ËÑË×ËÎ Ëô̰).
  • population mutation
    Áý´Ü±ºµ¹¿¬º¯ÀÌ(¡­ÔÍæÔܨì¶).
  • population policy
    Àα¸Á¤Ã¥(ÊÙËøÌ¤).
  • population problem
    Àα¸¹®Á¦.
  • population pyramid
    Àα¸¸ðÇü(ËöË´ËÎÌ´).
  • population screening
    Áý´Ü°ËÁø(̤ËÀ˧̤).
  • population trend
    Àα¸Ãß¼¼(ÊÙ̧ËÛ).
  • population variance
    ¸ðºÐ»ê(ËÎËÓË×).
  • stable population
    ¾ÈÁ¤Àα¸(ËâËøËöË´).
  • standard population
    Ç¥ÁØÀα¸(̡̰ËöË´).
  • stationary population
    Á¤ÁöÀα¸(ËøÌ¤ËöË´).
  • synchronous population
    µ¿Á¶¼¼Æ÷Áý´Ü
  • air study
    °ø±â(ÁÖÀÔ) °Ë»ç(¹ý)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CPK cell population kinetic [model]; creatine phosphokinase
CPS carbamoylphosphate synthetase; cardioplegic perfusion solution; centipoise; cervical pain syndrome; ...
GCP geriatric cancer population; granulocyte chemotactic protein
HARP homeless and at-risk population
MPD main pancreatic duct; maximum permissible dose; mean population doubling; membrane potential differe...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CPS Current Population Survey
EPESE Established Population for Epidemiologic Studies of the Elderly
NPHS National Population Health Survey
POHEM POpulation HEalth Model
PAR Population Attributable Risk
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • double-blind study
    ÀÌÁß ¸Í°Ë ¿¬±¸
  • electroencephalographic study
    ³úÆÄ °Ë»ç
  • enzyme marker study
    È¿¼Ò Ç¥Áö ¿¬±¸
  • longitudinal study
    ´©³âÀû ¿¬±¸, Á¾Àû ¿¬±¸, Á¾´Ü ¿¬±¸¹ý
  • microbiologic study
    »ý¹°ÇÐÀû °Ë»ç
  • microinjection study
    ¹Ì¼¼ ÁÖ»ç ¿¬±¸
  • mounted study cast
    ºÎÂøµÈ Áø´Ü ¸ðÇü
  • neurophysiological study
    ½Å°æ »ý¸®ÇÐÀû ¿¬±¸
  • phase 1 study
    ÀÓ»ó Á¦1»ó ½ÃÇè
  • prospective study
    ÀüÇâÀû ¿¬±¸, ÃßÀû ¿¬±¸
  • psychophysical study
    Á¤½Å ½ÅüÇÐ ¿¬±¸
  • psychophysiological study
    Á¤½Å »ý¸®ÇÐÀû ¿¬±¸
  • radionuclei study
    ÇÙ ¹æ»ç¼± ÃÔ¿µ
  • real time study
    ½Ç½Ã°£ °Ë»ç
  • secretory study
    ºÐºñ °Ë»ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
synchronous cell population <cell culture> A culture of cells that all divide in synchrony.
Particularly useful for certain studies of the cell cycle, cells can be made synchronous by depriving them of essential molecules, which are then restored. Synchronisation breaks down after a few cycles, however, as individual cells have unique division rates.
(19 Jan 1998)
q in population genetics The frequency of the less common of two different alternative (allelic) versions of a gene. (the frequency of the more common allele is p).
(12 Dec 1998)
topotypical population <zoology> Population occurring at the type locality from which the type specimen was taken.
(09 Jan 1998)
urban population The inhabitants of a city or town, including metropolitan areas and suburban areas.
(12 Dec 1998)
analytic study In epidemiology, a study designed to examine associations, commonly putative or hypothesised causal relationships; usually concerned with identifying or measuring the effects of risk factors or with the health effects of specific exposures.
(05 Mar 2000)
blinded study Clinical trials of drugs are often done blinded so that the patient does not know (is blinded as to) whether they are receiving the product being tested or the control/placebo to ensure that the results of a study are not affected by a possible placebo effect (by the power of suggestion).
(12 Dec 1998)
blind study A study in which the experimenter is unaware of which group is subject to which procedure.
(05 Mar 2000)
case-control study <epidemiology> A study in which the risk factors of people with a disease are compared with those without a disease.
It is an epidemiological method that begins by identifying persons with the disease or condition of interest (the cases) and compares their past history of exposure to identified or suspected risk factors with the past history of similar exposures among persons who resemble the cases but do not have the disease or condition of interest (the controls).
The relationship of an attribute to the disease can therefore be examined by comparing affected and non-affected individuals with regard to the frequency or levels of the attribute in each group.
(05 May 2002)
retrospective study <epidemiology> A study in which people are enrolled and then have their history of risks, infections or disease measured.
(05 Dec 1998)
rosenzweig picture-frustration study A projective test depicting cartoon-like characters in frustrating situations. The scoring of the subject's responses indicates the direction of hostility or aggression, that is, whether he blames himself, the other person, or the set of circumstances.
(12 Dec 1998)
cohort study A study using epidemiological methods, such as a clinical trial, in which a cohort with a particular attribute (e.g., smokers, recipients of a drug) is followed prospectively and compared for some outcome (e.g., disease, cure) with another cohort not possessing the attribute.
(05 Mar 2000)
pioped study <radiology> 251 patients with documented PE on pulmonary angiograms were given V/Q scans: 102 high probability, 105 intermediate probability, 39 low probability, 5 normal or near-normal
(12 Dec 1998)
multicenter study A controlled study executed by several cooperating institutions.
(12 Dec 1998)
multigeneration study Toxicity test in which at least 3 generations of the test organisms are exposed to the substance being assessed. Exposure is usually continuous.
Any medical study which follows a family of people through several generations.
(09 Oct 1997)
crossover study <statistics> A study that compares two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. Usually refers to a study in which the subject is switched from the experimental to the control procedure (or vice versa).
In the case of two treatments, a and b, half the subjects are randomly allocated to receive these in the order a, b and half to receive them in the order b, a.
A criticism of this design is that effects of the first treatment may carry over into the period when the second is given.
With this type of study, every patient serves as his or her own control.
(21 Jun 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • home study
    Åë½Å±³À°
  • nature study
    ÀÚ¿¬°øºÎ(²É »õ ±¤¼® ³¯¾¾µîÀÇ °üÂû,±¹¹ÎÇб³ÀÇ Çаú ''
  • study
    ½ÀÀÛ;½ÃÀÛ;¼­Àç;¿¬±¸½Ç;¾Ö¾¸
  • study
    ÇÏ´Ù;¾Ö¾²´Ù;(¹Ì)¼÷°íÇÏ´Ù
  • study
    ÇÏ´Ù;(´ë»çµîÀ»)¾Ï±âÇÏ´Ù
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á